2021
HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma
Cagaanan A, Stelter B, Vu N, Rhode EN, Stewart T, Hui P, Buza N, Al-Niaimi A, Flynn C, Weisman PS, McGregor SM. HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma. International Journal Of Gynecological Pathology 2021, 41: 132-141. PMID: 33782344, DOI: 10.1097/pgp.0000000000000783.Peer-Reviewed Original ResearchConceptsClear cell carcinomaEndometrial cancerSerous carcinomaCell carcinomaDiagnosis of CCCTraditional histologic classificationFuture clinical trialsAberrant p53 stainingBattery of immunostainsMajor diagnostic considerationCCC diagnosisMost HER2ER expressionEndometrioid carcinomaGynecologic pathologistsBeneficial therapyHER2 expressionHER2 statusP53 stainingClinical trialsDiagnostic difficultiesHistologic classificationDiagnostic considerationsAberrant p53Tissue microarray
2011
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF, B F. p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research 2011, 17: 5170-5178. PMID: 21693655, PMCID: PMC3149770, DOI: 10.1158/1078-0432.ccr-11-0484.Peer-Reviewed Original ResearchConceptsAddition of paclitaxelDoses of doxorubicinOverall survivalP53 protein expressionAdjuvant doxorubicinDose escalationBreast cancerP53 expressionNode-positive breast cancer patientsNode-positive breast cancerEarly-stage breast cancerCycles of cyclophosphamideNode-positive patientsProtein expressionStage II patientsBreast cancer patientsRandomized clinical trialsWorse RFSWorse OSII patientsPredictive factorsWorse prognosisCancer patientsP53 positivityP53 staining
2010
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells
Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2010, 117: 2567-2576. PMID: 21068437, PMCID: PMC3062351, DOI: 10.1182/blood-2010-07-295238.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Diamond-BlackfanAnemia, MacrocyticAnimalsBenzothiazolesCell CycleCell LineageCell NucleolusChromosome DeletionChromosomes, Human, Pair 5Cyclin-Dependent Kinase Inhibitor p21Erythroid Precursor CellsHaploinsufficiencyHematopoiesisHumansImidazolesMiceMice, Inbred BALB CMyelodysplastic SyndromesPiperazinesProtein BindingProto-Oncogene Proteins c-mdm2Ribosomal ProteinsRNA, Small InterferingTolueneTumor Suppressor Protein p53ConceptsErythroid progenitor cellsDiamond-Blackfan anemiaMyelodysplastic syndromeProgenitor cellsInduction of p53Bone marrow biopsyErythroid lineageNuclear p53 stainingFailure of erythropoiesisBone marrow failureHuman erythroid progenitor cellsMarrow biopsyHematopoietic progenitor cellsP53 stainingHuman hematopoietic progenitor cellsCell cycle arrestPharmacologic inhibitionMarrow failureNutlin-3Consequent cell cycle arrestP53 pathwayCycle arrestSelective impairmentExpression of shRNAsP53
2006
Differential Cell Cycle–Regulatory Protein Expression in Biliary Tract Adenocarcinoma: Correlation With Anatomic Site, Pathologic Variables, and Clinical Outcome
Jarnagin W, Klimstra D, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo R, D'Angelica M, Blumgart L, Singh B. Differential Cell Cycle–Regulatory Protein Expression in Biliary Tract Adenocarcinoma: Correlation With Anatomic Site, Pathologic Variables, and Clinical Outcome. Journal Of Clinical Oncology 2006, 24: 1152-1160. PMID: 16505435, DOI: 10.1200/jco.2005.04.6631.Peer-Reviewed Original ResearchMeSH KeywordsAgedBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorCell Cycle ProteinsCholangiocarcinomaCyclin D1Cyclin-Dependent Kinase Inhibitor p21FemaleGallbladder NeoplasmsGene Expression Regulation, NeoplasticHumansImmunohistochemistryKi-67 AntigenMaleMiddle AgedNeoplasm Recurrence, LocalProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mdm2Survival AnalysisTumor Suppressor Protein p53Up-RegulationConceptsBiliary tract adenocarcinomaPathological variablesProtein expressionAnatomical sitesP27 expressionParaffin-embedded surgical specimensTumor site of originImmunohistochemical expression of p53Cyclin D1Aberrant p53 stainingDistal bile ductExpression of p53Cyclin D1 overexpressionOverexpression of MDM2Cell cycle-regulatory proteinsSite of originHilar tumorsR0 resectionP53 stainingPapillary tumorsPrognostic roleSurgical specimensTumor locationSclerosing tumorsHilar cholangiocarcinoma
2002
Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer
Johnson E, Klimstra D, Herndon J, Catalano E, Canellos G, Graziano S, Kern J, Green M. Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer. Cancer Investigation 2002, 20: 686-692. PMID: 12197224, DOI: 10.1081/cnv-120003537.Peer-Reviewed Original ResearchConceptsCell lung cancerP53 stainingResistance to cisplatinLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerLung cancerMediastinal lymph node specimensNon-small cell lung cancerLeukemia Group B protocolsNonsmall cell lung cancerTumor resistance to cisplatinPartial resection ratePositive p53 stainingPost-operative chemotherapyResponse to chemotherapyAberrant p53 stainingGroup B protocolMutation of p53Lymph node specimensResistance in vitroPlatinum regimensMedian survivalStage IIIAResection rateStaging mediastinoscopy
1999
p53, mdm-2, and p21 waf-1 in the Porokeratoses
Nelson C, Cowper S, Morgan M. p53, mdm-2, and p21 waf-1 in the Porokeratoses. American Journal Of Dermatopathology 1999, 21: 420. PMID: 10535569, DOI: 10.1097/00000372-199910000-00003.Peer-Reviewed Original ResearchConceptsTypes of porokeratosisCyclin-dependent kinase inhibitor p21P53 stainingP53 tumor suppressor gene productCornoid lamellaP21 expressionPorokeratosesCell cycle progressionMdm-2Waf-1Inhibitor p21Potential roleTumor suppressor gene productP53 tumor suppressor proteinP21 proteinSuppressor gene productCycle progressionMDM2Tumor suppressor proteinGene productsP53Cell cycle controlPrevious findingsP21Suppressor protein
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply